Immusoft Presents First Patient Treated with Engineered B Cell

Biotech firm showcases pioneering gene therapy for rare diseases.

Apr. 8, 2026 at 12:47pm by Ben Kaplan

Got story updates? Submit your updates here. ›

Immusoft, a clinical-stage biotechnology company based in San Francisco, has announced the successful treatment of the world's first patient using an engineered B cell, a groundbreaking advancement in gene therapy that could pave the way for new treatments for rare and genetic diseases.

Why it matters

This milestone represents a significant step forward in the field of gene therapy, as engineered B cells offer the potential to safely and effectively deliver therapeutic genes to patients with rare genetic disorders. If proven effective, this approach could transform the treatment landscape for many underserved patient populations.

The details

Immusoft's proprietary technology platform involves extracting a patient's own B cells, engineering them to produce a desired therapeutic protein, and then reintroducing the modified cells back into the patient's body. In the case of the world's first treated patient, the engineered B cells were designed to produce an enzyme that is deficient in a rare genetic disorder.

  • Immusoft announced the successful treatment on April 8, 2026.

The players

Immusoft

A clinical-stage biotechnology company based in San Francisco that is pioneering the use of engineered B cells for gene therapy.

Got photos? Submit your photos here. ›

What they’re saying

“This breakthrough represents years of dedicated research and development, and we are thrilled to have successfully treated our first patient using this innovative approach.”

— Ernie Toth, CEO, Immusoft

What’s next

Immusoft plans to continue its clinical trials and work towards regulatory approval for this groundbreaking gene therapy approach.

The takeaway

Immusoft's successful treatment of the world's first patient with an engineered B cell marks a significant milestone in the field of gene therapy, offering hope for new treatments for rare and genetic diseases.